Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

作者：Shilpa Gupta, Yohann Loriot, Michiel S. van der Heijden, Jens Bedke, Begoña P. Valderrama, Eiji Kikuchi, Aude Fléchon, Daniel P. Petrylak, Maria De Santis, Matthew D. Galsky, Jae‐Lyun Lee, Umang Swami, Srikala S. Sridhar, Ugo De Giorgi, Phoebe Wright, Vanessa Shih, Yi‐Tsung Lu, Xuesong Guan, Ryan Dillon, Aditya Shetty, Blanca Homet Moreno, Jennifer L. Beaumont, Intan Purnajo, Shauna McManus, Thomas Powles · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00158-5 · 被引用次数：28 · 研究领域：Bladder and Urothelial Cancer Treatments、Cholangiocarcinoma and Gallbladder Cancer Studies、Cancer Immunotherapy and Biomarkers